IAS 10

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

Retrieved on: 
Friday, March 8, 2024
CFO, Acquisition, Certification, Fortnight, Requirement, News, File, FRA, IAS, Ontario Securities Commission, OSC, DMCL, Documentation, IMV, National Policy, National instrument, IAS 10

VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

Key Points: 
  • VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
  • The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company.
  • The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order.
  • The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

Retrieved on: 
Wednesday, March 6, 2024
CFO, Acquisition, Certification, Fortnight, Requirement, News, File, FRA, IAS, Ontario Securities Commission, OSC, DMCL, Documentation, IMV, National Policy, National instrument, IAS 10

VANCOUVER, BC, March 6, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

Key Points: 
  • VANCOUVER, BC, March 6, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
  • The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company.
  • The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order.
  • The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

Retrieved on: 
Friday, March 8, 2024
CFO, Acquisition, Certification, Fortnight, Requirement, News, File, FRA, IAS, Ontario Securities Commission, OSC, DMCL, Documentation, IMV, National Policy, National instrument, IAS 10

VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

Key Points: 
  • VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
  • The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company.
  • The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order.
  • The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

Annual Financial Statements Update for the Year Ended October 31, 2023

Retrieved on: 
Wednesday, February 21, 2024
Acquisition, Person, Requirement, News, File, FRA, IAS, Ontario Securities Commission, OSC, DMCL, Documentation, National Policy, National instrument, Policy, DPX, IAS 10, Bank statement, Audit

Under National Instrument 51-102, the Required Filings are required to be made not later than February 28, 2024 (the " Filing Deadline").

Key Points: 
  • Under National Instrument 51-102, the Required Filings are required to be made not later than February 28, 2024 (the " Filing Deadline").
  • The Company believes that this acquisition constitutes a major purchase of assets that must be reported in its financial statement in accordance with IAS 10.
  • The Company continues to work to complete the Company's annual financial statements, and expects to file the Required Filings by March 30, 2024, and will issue a news release once the Required Filings have been filed.
  • The Company's auditors have also made significant efforts to complete its audit of the annual financial statements.

Correction of a release from 15.11.2023 16:48 CET/CEST - 2CRSi SA: Availability of the annual financial report

Retrieved on: 
Saturday, December 30, 2023
Correction, Sale, Confidentiality, Next, Annual general meeting, Bank statement, Audit, IAS 10, Appendix, Market, IAS, AMF

Correction of a release from 15.11.2023 16:48 CET/CEST - 2CRSi SA: Availability of the annual financial report

Key Points: 
  • Correction of a release from 15.11.2023 16:48 CET/CEST - 2CRSi SA: Availability of the annual financial report
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • Strasbourg (France), November 15th, 2023 - 2CRSi (ISIN code: FR0013341781), designer and
    manufacturer of high-performance energy-efficient IT solutions, announces the
    publication of its 2022/23 annual financial report.
  • 2CRSi announces that, as of today, its definitive 2022/23 annual financial report (for the period March 1, 2022 to February 28, 2023), including the Auditors' reports, is now available to the public on its website.
  • The Auditors have expressed a qualified opinion on 2CRSi’s consolidated accounts concerning the estimated financial impact of the sale of Boston Limited.

2CRSi SA: Availability of the annual financial report

Retrieved on: 
Thursday, December 14, 2023
Bank statement, ISIN, Annual general meeting, Audit, IAS, Confidentiality, IAS 10, Regulatory News Service, Next, Sale, Financial Markets Authority, Security (finance), Cryptocurrency, Book, Euronext

Strasbourg (France), November 15th, 2023 - 2CRSi (ISIN code: FR0013341781), designer and

Key Points: 
  • Strasbourg (France), November 15th, 2023 - 2CRSi (ISIN code: FR0013341781), designer and
    manufacturer of high-performance energy-efficient IT solutions, announces the
    publication of its 2022/23 annual financial report.
  • 2CRSi announces that, as of today, its definitive 2022/23 annual financial report (for the period March 1, 2022 to February 28, 2023), including the Auditors' report, is now available to the public on its website.
  • The Auditors have expressed a qualified opinion concerning the estimated financial impact of the sale of Boston Limited.
  • Contrary to the provisions of IAS 10, the notes do not mention the estimated financial impact on the Group's financial statements of this significant subsequent event."